Company Overview and News
RESTON, Va., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Lightbridge Corporation (NASDAQ: LTBR), a U.S. nuclear fuel technology company, today announced that Ambassador Thomas Graham, Executive Chairman of Lightbridge Corporation, was a featured speaker on a panel discussion on the nuclear weapons disarmament process at the United Nations on October 9, 2018.
2018-08-28 globenewswire - 1
RESTON, Va., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Enfission, LLC has been named the 2018 Deal of Distinction for the chemicals, energy, environment and materials sector by the Licensing Executives Society (USA and Canada), Inc. (LES). Enfission is a joint venture between Lightbridge Corporation (NASDAQ: LTBR), a nuclear fuel technology development company, and Framatome, a leader in nuclear energy. LES will formally present the award on Oct.
RESTON, Va., Aug. 20, 2018 (GLOBE NEWSWIRE) -- Lightbridge Corporation (NASDAQ: LTBR), a U.S. nuclear fuel technology company, today announced the appointment of Larry Goldman as Chief Financial Officer and Barbara Kanakry as Controller, effective September 1, 2018. Linda Zwobota, Lightbridge’s current CFO will retire on September 1, 2018. Ms. Zwobota will continue working for the Company as a part-time consultant.
RESTON, Va., Aug. 17, 2018 (GLOBE NEWSWIRE) -- Enfission, LLC, a joint venture of Lightbridge Corporation (NASDAQ: LTBR), a nuclear fuel technology development company, and Framatome, a leader in nuclear energy, held its first meeting on August 15, 2018 with representatives of the U.S. Nuclear Regulatory Commission (NRC) to discuss the development and regulatory licensing of Lightbridge Fuel™ for the U.
RESTON, Va., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Lightbridge Corporation (NASDAQ:LTBR), a nuclear fuel technology development company, announced today that work began at the Framatome fuel fabrication facility in Richland, Washington. This state-of-the-art facility will be used to manufacture fuel assemblies for U.S. nuclear power plants based on Lightbridge’s patented metallic fuel that provides improved safety and better economics through power uprates and longer fuel cycles.
ltbr_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
ltbr_10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
RESTON, Va., July 20, 2018 (GLOBE NEWSWIRE) -- Lightbridge Corporation (NASDAQ:LTBR), a nuclear fuel developer, today announced that Seth Grae, CEO of Lightbridge, is scheduled to appear on Countdown to the Closing Bell with Liz Claman on the Fox Business Network at approximately 3:15 PM Eastern time today to discuss the future role of nuclear power in the United States and the impact Lightbridge’s advanced metallic fuel may have on the market.
2018-06-27 globenewswire - 2
Reaffirms Plans to Commence Testing of Fuel in a U.S. Research Reactor By 2020 and Deploy Lead Test Rod in a U.S. Commercial Reactor By 2021
RESTON, Va. , June 27, 2018 (GLOBE NEWSWIRE) -- Lightbridge Corporation (NASDAQ:LTBR), a nuclear fuel developer, today announced that Jonathan Baggett, Vice President of Program Management and Deputy Nuclear Quality Assurance Manager, will participate in a panel discussion entitled “Suppliers Perspective” at 1:15 PM, ET on Thursday, June 28 at The James Martin Center for Nonproliferation Studies, in Washington, DC.
RESTON, Va., June 19, 2018 (GLOBE NEWSWIRE) -- Executives from Enfission, LLC, a joint venture between Lightbridge Corporation (NASDAQ:LTBR), a nuclear fuel developer, and Framatome, a global leader in nuclear fuel, components, and reactor services, will present its cutting-edge metallic fuel technology at a workshop during the World Nuclear Exhibition on June 28 at 12:00 p.m. local Paris time. At the workshop, Enfission CEO Seth Grae and Enfission Project Director Aaron Totemeier will provide an overview of the development of the Lightbridge Fuel technology, designed to make existing and new nuclear power plants significantly more efficient and cost competitive.
RESTON, Va., June 18, 2018 (GLOBE NEWSWIRE) -- Lightbridge Corporation (NASDAQ:LTBR), a U.S. nuclear fuel development company, today announced that it has appointed James D. Fornof, PE, CFA, as Vice President for Government Program Management. In this new role, Mr. Fornof will provide leadership, management and oversight of projects involving government funding, as well as assist the company with implementation of corporate goals and strategic initiatives.
RESTON, Va., May 21, 2018 (GLOBE NEWSWIRE) -- Enfission CEO Seth Grae will provide an update at the Nuclear Energy Institute's annual conference May 22 on the development of the company's metallic fuel technology designed to make both existing and new nuclear power plants more efficient and economical. Enfission is a joint venture of Lightbridge Corporation (NASDAQ:LTBR), a nuclear fuel developer, and Framatome, a global supplier of nuclear fuel, plants and services.
MHVYF LTBR 7011
NEW YORK, May 16, 2018 (GLOBE NEWSWIRE) -- Lightbridge Corporation (NASDAQ:LTBR), a U.S. nuclear fuel development company, today announced that it will be presenting at the 19th Annual B. Riley Institutional Investor Conference on Thursday, May 24, 2018 at 2:30 PM, PST. The conference is being held May 23-24, 2018 at the Loews Santa Monica Beach Hotel in Santa Monica, California. Seth Grae, President and CEO of Lightbridge, will be presenting and providing recent business highlights at the event, as well as meeting with investors.
2018-05-13 seekingalpha - 1
Greetings and welcome to the Lightbridge 2018 First Quarter Earnings and Business Update Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder this conference is being recorded.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to LTBR / Lightbridge Corp. on message board site Silicon Investor.
|What is Thorium||What is Thorium||What is Thorium|
as of ET